about
Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzeeAdaptive Laboratory Evolution of Antibiotic Resistance Using Different Selection Regimes Lead to Similar Phenotypes and Genotypes.A decade of viral mutations and associated drug resistance in a population of HIV-1+ Puerto Ricans: 2002-2011CROI 2017: Advances in Antiretroviral Therapy.Decoding HIV resistance: from genotype to therapy.Impact of HIV-1 Integrase L74F and V75I Mutations in a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors.High Rates of Transmission of Drug-resistant HIV in Aruba Resulting in Reduced Susceptibility to the WHO Recommended First-line Regimen in Nearly Half of Newly Diagnosed HIV-infected Patients.Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update.Using a novel cellular platform to optimize CRISPR/CAS9 technology for the gene therapy of AIDS.Upward trends of acquired drug resistances in Ethiopian HIV-1C isolates: A decade longitudinal study.Transmission Dynamics of HIV-1 Drug Resistance among Treatment-Naïve Individuals in Greece: The Added Value of Molecular Epidemiology to Public Health.High Levels of Dual-Class Drug Resistance in HIV-Infected Children Failing First-Line Antiretroviral Therapy in Southern Ethiopia.The Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure.Effect of HIV/HCV Co-Infection on the Protease Evolution of HIV-1B: A Pilot Study in a Pediatric Population.A computational study for rational HIV-1 non-nucleoside Reverse Transcriptase inhibitor selection and discovery of novel allosteric pockets for inhibitor design.Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations.Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data.Impact of Antiretroviral Regimens on CSF Viral Escape in a Prospective Multicohort Study of ART-Experienced HIV-1 Infected Adults in the United States.Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa.Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance.HIV-1 integrase strand-transfer inhibitor resistance in southern Taiwan.Patterns of emergent resistance-associated mutations after initiation of non-nucleoside reverse-transcriptase inhibitor-containing antiretroviral regimens in Taiwan: a multicenter cohort study.Genotyping performance evaluation of commercially available HIV-1 drug resistance test.Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-]pyrimidine non-nucleoside inhibitorsStructural Implications of Genotypic Variations in HIV-1 Integrase From Diverse SubtypesDrug Resistance Mutation L76V Alters Nonpolar Interactions at the Flap-Core Interface of HIV-1 ProteasePharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamicsPrevious antiretroviral drug use compromises standard first-line HIV therapy and is mediated through drug-resistanceHIV-1 genotypic drug resistance in patients with virological failure to single-tablet antiretroviral regimens in southern TaiwanHIV-1 Protease Evolvability Is Affected by Synonymous Nucleotide Recoding
P2860
Q33442370-486E4B9B-64A2-40A9-B4B2-EBAB0389E096Q33659055-4CF6A885-5553-447F-A732-CC6A6EC6C1FAQ33664179-EBEEC5E5-835E-48DD-8A2B-79B7DF25B3ADQ38158950-AE000AF3-5D3A-4A62-85EC-C4759ECFBD80Q38632663-7D0FE981-E52B-4CCD-9FE7-F75C6E66728BQ40190127-EF0C8024-8CCD-4883-87DD-61F68DD9F866Q40280080-F504CD96-F98E-49BE-9BD0-C5A5B9E78465Q41926589-5E900AA4-83B3-4F46-83AC-279072BF04F4Q45870970-C11EB3B5-13A6-4DB1-B728-21D6223F2C0EQ46662332-855CD638-B50A-4264-98FF-FC3201F6971DQ47142324-054584E2-391D-4406-B264-E861041CCEE4Q47547186-5014B2C4-4796-479C-9513-B5AF59276105Q47569409-24226FA4-AC1B-4DB2-BF84-15EBAF124694Q49363062-817D3578-0A82-4155-A6F1-BCE58A5BFF86Q50043498-4A81ADB5-568C-4EB1-A637-297E65FB8DD9Q50070825-90336B70-30BE-4882-90DB-3BFCAD5A685DQ52319934-FDBD8ABF-D238-49C0-A863-0004497A9242Q52607097-3929BE00-7A8C-43DA-8799-FB0D71763A53Q52642470-9147DB81-6C62-443B-A3D3-5DAF2948904FQ52671185-3071B5F5-6940-4378-9F98-515F280E6C56Q55060074-FD061E1E-F888-42BA-B5BE-5D1E0C7E8539Q55333264-C5D3BD4C-8FCA-4016-929A-6A357F14C02BQ55456202-B890F198-DBE3-476C-AC56-38CCF50D37B6Q56531878-5B90E26B-FCBA-4AE9-BC94-734D8299B94AQ56926444-7E4AE524-B5C1-431F-ADEA-6182B123DFA4Q57063482-B9EFC7BB-D07C-40F0-902F-D0B488F348C2Q57403878-D513A2AF-D595-4AE4-BAD9-54FDFBBEBA53Q58563027-B72B93C4-F011-4392-B382-AACDA8CED953Q58801941-8DB365E9-E6BE-4142-B83D-4C32B05FDAC3Q58861509-96587E8F-4E2E-42A2-943A-4DA2C52F0EDE
P2860
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
2017 Update of the Drug Resistance Mutations in HIV-1.
@en
type
label
2017 Update of the Drug Resistance Mutations in HIV-1.
@en
prefLabel
2017 Update of the Drug Resistance Mutations in HIV-1.
@en
P2093
P2860
P1476
2017 Update of the Drug Resistance Mutations in HIV-1.
@en
P2093
Annemarie M Wensing
Douglas D Richman
Robert W Shafer
Roger Paredes
Victoria A Johnson
Vincent Calvez
P2860
P304
P577
2017-12-01T00:00:00Z